1.    PDF File (agradoc61.pdf 44 Kb)
Zippe, C., Pandrangi, L., and Agarwal, A. (1999):
NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer.
J Urol 161:62-65.
 

2.    PDF File (agradoc66.pdf 54 Kb)
Sharma, S., Zippe, C.D., Pandrangi, L., Nelson, D., and Agarwal, A. (1999):
Exclusion criteria enhances specificity of NMP22 and BTA Stat.
J Urol 162:53-57.
 

3.      PDF File (agradoc072.pdf  605 Kb)
Zippe, C., Pandrangi, L., Potts, J.M., Kursh, E., Novick, A., and Agarwal, A. (1999):
NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer.
Anticancer Res 19:2621-2623.
 

4.    PDF File (agradoc94.pdf 55 Kb)
Ponsky, L.E., Sharma, S., Pandrangi, L., Kedia, S., Nelson, D.R., Agarwal, A., and Zippe, C.D. (2001):
Screening and monitoring for bladder cancer: refining the use of NMP22.
J Urol 166:75-78.
 

5.    PDF File (agradoc220.pdf    394 Kb)
Raina, R, Agarwal, A, Zippe, CD (2006):
Indexing atypical cytology in bladder cancer to NMP22 decreases false-positive results-can it replace surveillance cystoscopy? Business Briefing.
US Genito-Urinary Disease 2006:36-38.
 

6.    PDF File (agradoc309.pdf    106 Kb)   
Raina R, Pahlajani G, Ponsky LE, Agarwal A, Zippe CD (2008):
The clinical utility of atypical cytology is significantly increased in both screening and monitoring for bladder cancer when indexed with nuclear matrix protein-22.
BJU Int. 102:297-300.